531 related articles for article (PubMed ID: 11871491)
21. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates.
Saravolatz LD; Pawlak J; Johnson LB
Clin Infect Dis; 2012 Aug; 55(4):582-6. PubMed ID: 22615331
[TBL] [Abstract][Full Text] [Related]
22. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia).
Saha B; Singh AK; Ghosh A; Bal M
J Med Microbiol; 2008 Jan; 57(Pt 1):72-79. PubMed ID: 18065670
[TBL] [Abstract][Full Text] [Related]
23. Dissemination of antibiotic resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant S aureus strains isolated from hospital effluents.
Mandal SM; Ghosh AK; Pati BR
Am J Infect Control; 2015 Dec; 43(12):e87-8. PubMed ID: 26422180
[TBL] [Abstract][Full Text] [Related]
24. Effect of sub-lethal doses of vancomycin and oxacillin on biofilm formation by vancomycin intermediate resistant Staphylococcus aureus.
Mirani ZA; Jamil N
J Basic Microbiol; 2011 Apr; 51(2):191-5. PubMed ID: 20967790
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
Saravolatz LD; Pawlak J; Johnson LB; Saravolatz LD; Husain N
Int J Antimicrob Agents; 2010 Nov; 36(5):478-80. PubMed ID: 20846830
[No Abstract] [Full Text] [Related]
26. Staphylococcus aureus VRSA-11B is a constitutive vancomycin-resistant mutant of vancomycin-dependent VRSA-11A.
Périchon B; Courvalin P
Antimicrob Agents Chemother; 2012 Sep; 56(9):4693-6. PubMed ID: 22710116
[TBL] [Abstract][Full Text] [Related]
27. Evolution of antibiotic resistance in gram-positive pathogens.
Marchese A; Schito GC; Debbia EA
J Chemother; 2000 Dec; 12(6):459-62. PubMed ID: 11154025
[TBL] [Abstract][Full Text] [Related]
28. VRSA-doomsday superbug or damp squib?
Gould IM
Lancet Infect Dis; 2010 Dec; 10(12):816-8. PubMed ID: 21109164
[No Abstract] [Full Text] [Related]
29. Mechanisms of vancomycin resistance in Staphylococcus aureus.
Gardete S; Tomasz A
J Clin Invest; 2014 Jul; 124(7):2836-40. PubMed ID: 24983424
[TBL] [Abstract][Full Text] [Related]
30. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
Cui L; Tominaga E; Neoh HM; Hiramatsu K
Antimicrob Agents Chemother; 2006 Mar; 50(3):1079-82. PubMed ID: 16495273
[TBL] [Abstract][Full Text] [Related]
31. Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient--importance of low-level resistance to vancomycin.
Haraga I; Nomura S; Fukamachi S; Ohjimi H; Hanaki H; Hiramatsu K; Nagayama A
Int J Infect Dis; 2002 Dec; 6(4):302-8. PubMed ID: 12718825
[TBL] [Abstract][Full Text] [Related]
32. Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.
Tabuchi F; Matsumoto Y; Ishii M; Tatsuno K; Okazaki M; Sato T; Moriya K; Sekimizu K
J Antibiot (Tokyo); 2017 Jun; 70(6):771-774. PubMed ID: 28196977
[TBL] [Abstract][Full Text] [Related]
33. D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.
Tabuchi F; Matsumoto Y; Ishii M; Tatsuno K; Okazaki M; Sato T; Moriya K; Sekimizu K
J Antibiot (Tokyo); 2017 Jul; 70(8):907-910. PubMed ID: 28588223
[TBL] [Abstract][Full Text] [Related]
34. Genomic organization of a vancomycin-resistant Staphylococcus aureus.
Mirani ZA; Jamil N
J Coll Physicians Surg Pak; 2013 Feb; 23(2):107-11. PubMed ID: 23374512
[TBL] [Abstract][Full Text] [Related]
35. Single-nucleotide polymorphisms in a vancomycin-resistant Staphylococcus aureus strain based on whole-genome sequencing.
Kim JW; Lee KJ
Arch Microbiol; 2020 Oct; 202(8):2255-2261. PubMed ID: 32535788
[TBL] [Abstract][Full Text] [Related]
36. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.
Whitener CJ; Park SY; Browne FA; Parent LJ; Julian K; Bozdogan B; Appelbaum PC; Chaitram J; Weigel LM; Jernigan J; McDougal LK; Tenover FC; Fridkin SK
Clin Infect Dis; 2004 Apr; 38(8):1049-55. PubMed ID: 15095205
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of vancomycin-beta-lactam combinations against heterogeneously vancomycin-resistant Staphylococcus aureus (hetero-VRSA).
Kim YS; Kiem S; Yun HJ; Jung SI; Oh WS; Kim SW; Peck KR; Lee NY; Song JH
J Korean Med Sci; 2003 Jun; 18(3):319-24. PubMed ID: 12808315
[TBL] [Abstract][Full Text] [Related]
38. [Infections of vancomycin resistant enterococci (VRE) and Staphylococcus aureus (VRSA)].
Kuwahara K; Hanaki H; Hiramatsu K
Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):182-5. PubMed ID: 10088368
[No Abstract] [Full Text] [Related]
39. Staphylococcus aureus with reduced susceptibility to vancomycin.
Cosgrove SE; Carroll KC; Perl TM
Clin Infect Dis; 2004 Aug; 39(4):539-45. PubMed ID: 15356818
[TBL] [Abstract][Full Text] [Related]
40. Nanoconjugated vancomycin: new opportunities for the development of anti-VRSA agents.
Chakraborty SP; Sahu SK; Mahapatra SK; Santra S; Bal M; Roy S; Pramanik P
Nanotechnology; 2010 Mar; 21(10):105103. PubMed ID: 20154376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
